{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:17:21Z","timestamp":1783394241857,"version":"3.54.6"},"reference-count":16,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.urolonc.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T15:42:34Z","timestamp":1748014954000},"page":"522.e9-522.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic role of pathological substaging in high-grade pT1 bladder cancer undergoing BCG therapy: Insights on recurrence and progression"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0731-9877","authenticated-orcid":false,"given":"Kemal","family":"Kayar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-919X","authenticated-orcid":false,"given":"Ridvan","family":"Kayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1654-8524","authenticated-orcid":false,"given":"Emre","family":"Karabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3498-0628","authenticated-orcid":false,"given":"Bugrahan Buhur","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8221-8158","authenticated-orcid":false,"given":"Cagatay","family":"Tosun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5704-6160","authenticated-orcid":false,"given":"Gulistan","family":"Gumrukcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1868-2316","authenticated-orcid":false,"given":"Metin Ishak","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8161-4068","authenticated-orcid":false,"given":"Omer Ergin","family":"Yucebas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2025.05.004_bib0001","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Lotan Y., et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"van Rhijn","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.05.004_bib0002","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1464-410X.2008.07743.x","article-title":"Invasive T1 bladder cancer: indications and rationale for radical cystectomy","volume":"102","author":"Stein","year":"2008","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2025.05.004_bib0003","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.05.004_bib0004","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2559.2011.03989.x","article-title":"Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series","volume":"59","author":"Bertz","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.urolonc.2025.05.004_bib0005","doi-asserted-by":"crossref","unstructured":"Orsola A., Trias I., Ravent\u00f3s C. X., et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a\/b\/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005;48(2):231\u2013238. discussion 238.","DOI":"10.1016\/j.eururo.2005.04.013"},{"issue":"8","key":"10.1016\/j.urolonc.2025.05.004_bib0006","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1464-410X.2012.10996.x","article-title":"Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer","volume":"110","author":"van Rhijn","year":"2012","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.urolonc.2025.05.004_bib0007","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/bjc.2014.633","article-title":"de Torres I., et al. Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients","volume":"112","author":"Orsola","year":"2015","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2025.05.004_bib0008","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.euf.2016.12.011","article-title":"Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"4","author":"Naselli","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.urolonc.2025.05.004_bib0009","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.juro.2006.08.070","article-title":"Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?","volume":"177","author":"Herr","year":"2007","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.05.004_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-020-02808-6","article-title":"Mazzucchelli R., et al. pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging","volume":"477","author":"Raspollini","year":"2020","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.urolonc.2025.05.004_bib0011","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11255-020-02772-9","article-title":"Prognosis of patients with T1 bladder cancer after en bloc transurethral resection of bladder tumor stratified by invasion to the level of the muscularis mucosa","volume":"53","author":"Yasui","year":"2021","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.05.004_bib0012","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000515650","article-title":"Substaging of pT1 urothelial bladder carcinoma predicts tumor progression and overall survival","volume":"106","author":"Grobet-Jeandin","year":"2022","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.urolonc.2025.05.004_bib0013","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0022-5347(05)67706-3","article-title":"Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma","volume":"163","author":"Kondylis","year":"2000","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.05.004_bib0014","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00345-019-02936-y","article-title":"Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis","volume":"38","author":"Kardoust Parizi","year":"2020","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.05.004_bib0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000355358","article-title":"The prognostic value of T1 bladder cancer substaging: a single institution retrospective study","volume":"92","author":"Soukup","year":"2014","journal-title":"Urol Int"},{"issue":"2","key":"10.1016\/j.urolonc.2025.05.004_bib0016","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1590\/s1677-5538.ibju.2017.0424","article-title":"Comparative differences between T1a\/b and T1e\/m as substages in T1 urothelial carcinoma of the bladder","volume":"44","author":"Turan","year":"2018","journal-title":"Int Braz J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:35:26Z","timestamp":1754912126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925001747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1078143925001747"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.05.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic role of pathological substaging in high-grade pT1 bladder cancer undergoing BCG therapy: Insights on recurrence and progression","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}